World health organization classification of myelodysplastic syndromes

Magdalena Czader, Attilio Orazi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Myelodysplastic syndromes (MDS) are characterized by an ineffective hematopoiesis and functional abnormalities of hematopoietic lineages. Patients with MDS present with cytopenia(s) associated with morphological dysplasia and /or increase in number of blasts, and can progress to acute myeloid leukemia. The pathogenesis of MDS is exceedingly complex and involves the hematopoietic stem cells, bone marrow microenvironment and an interaction between these two compartments. The laboratory diagnostic strategy in MDS has evolved significantly over the years from a purely morphological one based almost exclusively on peripheral blood smear and bone marrow aspirate cytology to the integrated multiparametric approach used in the 2001 and 2008 WHO classification schemes. An evolution has also occurred in the prognostic assessment and the evaluation of treatment response to include novel disease related factors as well as patient specific characteristics such as non-hematologic comorbidities. This progress in clinically relevant subclassification of MDS and inclusion of specific variables related to treatment response are particularly important considering the increasing treatment options available for MDS. This review is largely focused on the diagnostic approach to MDS including discussion of the significance of cytogenetic/genetic and immunophenotypic features. We present the overview of the minimal diagnostic criteria for diagnosing MDS and a detailed description the current World Health Organization (WHO) classification scheme.

Original languageEnglish
Pages (from-to)3149-3162
Number of pages14
JournalCurrent Pharmaceutical Design
Volume18
Issue number22
StatePublished - Jul 2012

Fingerprint

Myelodysplastic Syndromes
Bone Marrow
Hematopoiesis
Hematopoietic Stem Cells
Acute Myeloid Leukemia
Cytogenetics
Cell Biology
Comorbidity
Therapeutics

Keywords

  • 5q- syndrome
  • Cytogenetics
  • Flow cytometry
  • Histopathology
  • Immunohistochemistry
  • MDS
  • Myelodysplastic syndromes (MDS)
  • Pediatric MDS
  • Refractory anemia with excess blasts
  • Refractory cytopenia with multilineage dysplasia
  • Refractory cytopenia with unilineage dysplasia
  • Unclassifiable

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

World health organization classification of myelodysplastic syndromes. / Czader, Magdalena; Orazi, Attilio.

In: Current Pharmaceutical Design, Vol. 18, No. 22, 07.2012, p. 3149-3162.

Research output: Contribution to journalArticle

@article{fd86c0bb06e04e48ae3891e601965e94,
title = "World health organization classification of myelodysplastic syndromes",
abstract = "Myelodysplastic syndromes (MDS) are characterized by an ineffective hematopoiesis and functional abnormalities of hematopoietic lineages. Patients with MDS present with cytopenia(s) associated with morphological dysplasia and /or increase in number of blasts, and can progress to acute myeloid leukemia. The pathogenesis of MDS is exceedingly complex and involves the hematopoietic stem cells, bone marrow microenvironment and an interaction between these two compartments. The laboratory diagnostic strategy in MDS has evolved significantly over the years from a purely morphological one based almost exclusively on peripheral blood smear and bone marrow aspirate cytology to the integrated multiparametric approach used in the 2001 and 2008 WHO classification schemes. An evolution has also occurred in the prognostic assessment and the evaluation of treatment response to include novel disease related factors as well as patient specific characteristics such as non-hematologic comorbidities. This progress in clinically relevant subclassification of MDS and inclusion of specific variables related to treatment response are particularly important considering the increasing treatment options available for MDS. This review is largely focused on the diagnostic approach to MDS including discussion of the significance of cytogenetic/genetic and immunophenotypic features. We present the overview of the minimal diagnostic criteria for diagnosing MDS and a detailed description the current World Health Organization (WHO) classification scheme.",
keywords = "5q- syndrome, Cytogenetics, Flow cytometry, Histopathology, Immunohistochemistry, MDS, Myelodysplastic syndromes (MDS), Pediatric MDS, Refractory anemia with excess blasts, Refractory cytopenia with multilineage dysplasia, Refractory cytopenia with unilineage dysplasia, Unclassifiable",
author = "Magdalena Czader and Attilio Orazi",
year = "2012",
month = "7",
language = "English",
volume = "18",
pages = "3149--3162",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "22",

}

TY - JOUR

T1 - World health organization classification of myelodysplastic syndromes

AU - Czader, Magdalena

AU - Orazi, Attilio

PY - 2012/7

Y1 - 2012/7

N2 - Myelodysplastic syndromes (MDS) are characterized by an ineffective hematopoiesis and functional abnormalities of hematopoietic lineages. Patients with MDS present with cytopenia(s) associated with morphological dysplasia and /or increase in number of blasts, and can progress to acute myeloid leukemia. The pathogenesis of MDS is exceedingly complex and involves the hematopoietic stem cells, bone marrow microenvironment and an interaction between these two compartments. The laboratory diagnostic strategy in MDS has evolved significantly over the years from a purely morphological one based almost exclusively on peripheral blood smear and bone marrow aspirate cytology to the integrated multiparametric approach used in the 2001 and 2008 WHO classification schemes. An evolution has also occurred in the prognostic assessment and the evaluation of treatment response to include novel disease related factors as well as patient specific characteristics such as non-hematologic comorbidities. This progress in clinically relevant subclassification of MDS and inclusion of specific variables related to treatment response are particularly important considering the increasing treatment options available for MDS. This review is largely focused on the diagnostic approach to MDS including discussion of the significance of cytogenetic/genetic and immunophenotypic features. We present the overview of the minimal diagnostic criteria for diagnosing MDS and a detailed description the current World Health Organization (WHO) classification scheme.

AB - Myelodysplastic syndromes (MDS) are characterized by an ineffective hematopoiesis and functional abnormalities of hematopoietic lineages. Patients with MDS present with cytopenia(s) associated with morphological dysplasia and /or increase in number of blasts, and can progress to acute myeloid leukemia. The pathogenesis of MDS is exceedingly complex and involves the hematopoietic stem cells, bone marrow microenvironment and an interaction between these two compartments. The laboratory diagnostic strategy in MDS has evolved significantly over the years from a purely morphological one based almost exclusively on peripheral blood smear and bone marrow aspirate cytology to the integrated multiparametric approach used in the 2001 and 2008 WHO classification schemes. An evolution has also occurred in the prognostic assessment and the evaluation of treatment response to include novel disease related factors as well as patient specific characteristics such as non-hematologic comorbidities. This progress in clinically relevant subclassification of MDS and inclusion of specific variables related to treatment response are particularly important considering the increasing treatment options available for MDS. This review is largely focused on the diagnostic approach to MDS including discussion of the significance of cytogenetic/genetic and immunophenotypic features. We present the overview of the minimal diagnostic criteria for diagnosing MDS and a detailed description the current World Health Organization (WHO) classification scheme.

KW - 5q- syndrome

KW - Cytogenetics

KW - Flow cytometry

KW - Histopathology

KW - Immunohistochemistry

KW - MDS

KW - Myelodysplastic syndromes (MDS)

KW - Pediatric MDS

KW - Refractory anemia with excess blasts

KW - Refractory cytopenia with multilineage dysplasia

KW - Refractory cytopenia with unilineage dysplasia

KW - Unclassifiable

UR - http://www.scopus.com/inward/record.url?scp=84862586164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862586164&partnerID=8YFLogxK

M3 - Article

C2 - 22571693

AN - SCOPUS:84862586164

VL - 18

SP - 3149

EP - 3162

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 22

ER -